Most frequent adverse events observed in the study
| Placebo | GSK2798745 | Total | |
| Subjects n | 17 | 16 | 17 |
| Number of participants with any event | 9 (53) | 11 (69) | 13 (76) |
| Number of participants with a drug-related event | 2 (12) | 2 (13) | 4 (24) |
| Most common adverse events: (adverse events occurring in ≥2 participants in any treatment group) | |||
| Headache | 3 (18) | 7 (44) | 8 (47) |
| Diarrhoea | 2 (12) | 1 (6) | 3 (18) |
| Fatigue | 1 (6) | 2 (13) | 3 (18) |
| Oropharyngeal pain | 2 (12) | 0 | 2 (12) |
Data expressed as n (%) unless otherwise noted. Note: Adverse events were assigned to a treatment group based on the start date of the adverse events in relation to the study treatment period. Adverse events that started during the washout period were assigned to the Period 1 treatment group.